RAP-219
RAP-219-FOS-201
Phase 2 small_molecule completed
Quick answer
RAP-219 for Focal Onset Seizures is a Phase 2 program (small_molecule) at Rapport Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rapport Therapeutics
- Indication
- Focal Onset Seizures
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed